The meeting outlined the evidence that the use of magnetic resonance imaging (MRI) markers as surrogate endpoints in clinical trials of relapsing-remitting multiple sclerosis (MS) is both valid and informative.
Neurology
Login to continue
Members
Create Account
Create your own personal healthcare feed, full of the latest content from across our divisions.
Register